磷酸二酯酶及其抑制剂在心力衰竭中的研究现状  

Phosphodiesterase and its inhibitors in heart failure

作　　者：曾玉 郭文钧 樊天斐 冯小航 高冉[2] 王婧 ZENG Yu;GUO Wen-jun;FAN Tian-fei;FENG Xiao-hang;GAO Ran;WANG Jing(Inner Mongolia Medical University,School of Basic Medicine,Huhhot 010000,China;Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,School of Basic Medicine,Peking Union Medical College,Beijing 100730,China)

机构地区：[1]内蒙古医科大学基础医学院,内蒙古呼和浩特010000 [2]中国医学科学院基础医学研究所,北京协和医学院基础学院,北京100730

出　　处：《中国病理生理杂志》2022年第4期743-750,共8页Chinese Journal of Pathophysiology

基　　金：国家自然科学基金资助项目(No.82100514)。

摘　　要：心力衰竭简称心衰(heart failure,HF),是由于结构或功能性心脏异常引起心室充盈和(或)射血能力受损的一组慢性进行性临床综合征,其主要临床特征是肺循环淤血、心排血量降低和体循环淤血,表现为左心室射血分数(left ventricular ejection fraction,LVEF)降低(HF with reduced ejection fraction,HFrEF)或保留(HF with preserved ejection fraction,HFpEF)[1]。Cardiovascular diseases are the leading cause of death globally.Heart failure(HF)is the endstage manifestation of cardiovascular diseases,with a high incidence in the elderly population.The changes of cardiac molecules,structure and function are observed in HF.It is reported that cyclic guanosine monophosphate(cGMP)deficiency exacerbates the formation of HF,while phosphodiesterases(PDEs)contribute to degrading cGMP into inactive guanosine monophosphate(GMP).Therefore,inhibition of PDE is a potential therapy for HF.This paper reviews the pathogenesis of HF and the physiological functions of several PDE subtypes(PDE1-5,9 and 10)and their inhibitors in treatment of HF.

关 键 词：心力衰竭 磷酸二酯酶 磷酸二酯酶抑制剂 环磷酸鸟苷 

分 类 号：R541.6[医药卫生—心血管疾病] R363.2[医药卫生—内科学]